Filgrastim Biosimilars Global Market Report 2025

Description

Filgrastim biosimilars are biosimilars designed to address bone marrow damage caused by extremely high radiation doses, similar to their use in cancer patients. These biosimilars work by stimulating the production of white blood cells, reducing the susceptibility of patients to infections.

There are two primary manufacturing types for the filgrastim biosimilar market in-house manufacturing and contract manufacturing organization (CMO). A contract manufacturing organization, also known as a contract development and manufacturing organization, is a company that offers comprehensive services to other pharmaceutical firms on a contractual basis, covering activities from drug discovery to drug production. The diverse applications of filgrastim biosimilars include oncology, chronic and autoimmune diseases, blood disorders, growth hormone deficiency, infectious diseases, and others. These products are distributed through various channels, including hospital pharmacies, retail pharmacies, and online pharmacies.

The filgrastim biosimilar markets market research report is one of a series of new reports from The Business Research Company that provides filgrastim biosimilar markets market statistics, including filgrastim biosimilar markets industry global market size, regional shares, competitors with a filgrastim biosimilar markets market share, detailed filgrastim biosimilar markets market segments, market trends and opportunities, and any further data you may need to thrive in the filgrastim biosimilar markets industry. This filgrastim biosimilar markets market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The filgrastim biosimilars market size has grown strongly in recent years. It will grow from $0.92 billion in 2024 to $0.98 billion in 2025 at a compound annual growth rate (CAGR) of 6.9%. The growth in the historic period can be attributed to emerging markets growth, increase in patent expiration, government initiatives, increased healthcare expenditure, low cost of biosimilars, strong pipeline of drugs and increase in biopharmaceutical r&d expenditure.

The filgrastim biosimilars market size is expected to see strong growth in the next few years. It will grow to $1.21 billion in 2029 at a compound annual growth rate (CAGR) of 5.4%. The growth in the forecast period can be attributed to aging population, increase in healthcare access. Major trends in the forecast period include investing extensively in R&D activities for the development of effective and innovative biosimilars, production of biosimilars for neutropenia treatment to improve revenues and increasing their focus on M&A growth strategies.

The anticipated growth of the filgrastim biosimilar market is driven by the increasing prevalence of neutropenia. Neutropenia, a condition characterized by insufficient neutrophils, crucial white blood cells in infection defense, can be addressed with filgrastim biosimilars. These biosimilars stimulate neutrophil production in the bone marrow, elevating neutrophil counts and aiding in infection resistance. For example, data from August 2022, sourced from the National Center for Biotechnology Information, revealed neutropenia prevalence rates of 0.38% among Mexican-Americans, 0.79% among whites, and 4.5% among black participants. Consequently, the rising prevalence of neutropenia is a significant factor propelling the filgrastim biosimilar market's growth.

Government initiatives dedicated to biosimilar development are poised to contribute to the filgrastim biosimilar market's expansion in the coming years. Global governments are emphasizing biosimilar development due to its cost-effectiveness. Initiatives such as the US Food and Drug Administration's (FDA) Biosimilar Action Plan and Australia's commitment to the Biosimilar Awareness Initiative highlight a strategic focus on increasing treatment options and promoting biosimilar education. This support, including a $5 million grant from the Australian government to the Generic and Biosimilar Medicines Association, enhances awareness and activities related to biosimilar medicines' dispensing, prescription, and use. Thus, government initiatives play a pivotal role in fostering the growth of the filgrastim biosimilar market.

Prominent firms in the filgrastim biosimilar market are at the forefront of creating innovative products utilizing advanced technologies, such as recombinant DNA technology, to manufacture biosimilars. Recombinant DNA technology involves the creation of hybrid DNA by integrating a foreign sequence into an organism's DNA. For instance, in May 2023, Amneal Pharmaceuticals, a US-based pharmaceutical company, introduced FYLNETRA (pegfilgrastim-pbbk), a biosimilar to Amgen's NEULASTA in the United States. It is indicated for treating and preventing febrile neutropenia, facilitating neutrophil expansion, maturation, and enhanced viability and efficiency. FYLNETRA's launch aims to provide affordable medicines, expanding access for patients, providers, and payors.

Leading companies in the filgrastim biosimilar market continue to innovate with products such as Releuko (filgrastim-ayow) to better address patient needs. Releuko (filgrastim-ayow), referencing Neupogen (filgrastim), is designed for treating and preventing febrile neutropenia in cancer patients undergoing chemotherapy. In November 2022, Amneal Pharmaceuticals and Kashiv Biosciences, both US-based companies, jointly launched Releuko (filgrastim-ayow) in the US market. Contraindications include patients with a history of serious allergic reactions to human granulocyte colony-stimulating factors. This approval marks Amneal's debut in the biosimilar realm, with more decisions anticipated by year-end.

In March 2022, Biocon Biologics, an India-based fully integrated biopharmaceutical company, completed the acquisition of Viatris Inc. for $3.3 billion, creating a robust, globally integrated biosimilars enterprise. This strategic collaboration leverages the strengths and complementary expertise of both entities, positioning Biocon Biologics for a decade of value generation for stakeholders. Viatris Inc., a US-based pharmaceutical company, has developed a biosimilar of pegfilgrastim.

Major companies operating in the filgrastim biosimilars market include Teva Pharmaceutical Industries Ltd, Novartis International AG, Biocon Limited, Intas Biopharmaceuticals, Dr. Reddy's Laboratories, Pfizer, Cadila Healthcare Ltd, Reliance Life Science Pvt. Ltd, Gennova Biopharmaceuticals (Emcure), Sandoz Pty Ltd, Mylan, Lupin Limited, Coherus Biosciences Inc., North China Pharmaceutical Corporation, Tonghua Dongbaoare, Beijing SL Pharmaceutical, Fuji Pharma, Adello Biologics, Apobiologix (Apotex), Hospira, Tanvex BioPharma, Eurofarma Laboratorios

North America was the largest region in the filgrastim biosimilar markets market in 2024. Middle East is expected to be the fastest growing region in the global filgrastim biosimilar markets market during the forecast period. The regions covered in the filgrastim biosimilars market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the filgrastim biosimilars market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Canada, Spain

The filgrastim biosimilar markets consist of sales of Zarxio, Nivestym, and Releuko. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Filgrastim Biosimilars Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on filgrastim biosimilars market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on the latest market shares.
Benchmark performance against key competitors.
Suitable for supporting your internal and external presentations with reliable high quality data and analysis
Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for filgrastim biosimilars ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The filgrastim biosimilars market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The market characteristics section of the report defines and explains the market.
The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

Market segmentations break down the market into sub markets.
The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

Markets Covered:1) By Type Of Manufacturing: In-House Manufacturing, Contract Manufacturing organization
2) By Application: Oncology, Chronic And Autoimmune Diseases, Blood Disorders, Growth Hormone Deficiency, Other Applications
3) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy
Subsegments:
1) By In-House Manufacturing: Proprietary In-House Manufacturing Facilities; Company-Owned Production Plants; Vertically Integrated Manufacturing
2) By Contract Manufacturing Organization: Full-Service Contract Manufacturing; Fill and Finish Services; API (Active Pharmaceutical Ingredient) Manufacturing; Specialized Biosimilar Manufacturing Services
Companies Mentioned: Teva Pharmaceutical Industries Ltd; Novartis International AG; Biocon Limited; Intas Biopharmaceuticals; Dr. Reddy's Laboratories
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery format: PDF, Word and Excel Data Dashboard.

Product Code: r25637

1. Executive Summary

2. Filgrastim Biosimilars Market Characteristics

3. Filgrastim Biosimilars Market Trends And Strategies

4. Filgrastim Biosimilars Market - Macro Economic Scenario including the impact of Interest Rates, Inflation, Geopolitics and Covid And Recovery on the Market

5. Global Filgrastim Biosimilars Growth Analysis And Strategic Analysis Framework

5.1. Global Filgrastim Biosimilars PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
5.2. Analysis Of End Use Industries
5.3. Global Filgrastim Biosimilars Market Growth Rate Analysis
5.4. Global Filgrastim Biosimilars Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
5.5. Global Filgrastim Biosimilars Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
5.6. Global Filgrastim Biosimilars Total Addressable Market (TAM)

6. Filgrastim Biosimilars Market Segmentation

6.1. Global Filgrastim Biosimilars Market, Segmentation By Type Of Manufacturing, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
In-House Manufacturing
Contract Manufacturing Organization
6.2. Global Filgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Oncology
Chronic And Autoimmune Diseases
Blood Disorders
Growth Hormone Deficiency
Other Applications
6.3. Global Filgrastim Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Hospital Pharmacy
Retail Pharmacy
Online Pharmacy
6.4. Global Filgrastim Biosimilars Market, Sub-Segmentation Of In-House Manufacturing, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Proprietary In-House Manufacturing Facilities
Company-Owned Production Plants
Vertically Integrated Manufacturing
6.5. Global Filgrastim Biosimilars Market, Sub-Segmentation Of Contract Manufacturing Organization, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Full-Service Contract Manufacturing
Fill and Finish Services
API (Active Pharmaceutical Ingredient) Manufacturing
Specialized Biosimilar Manufacturing Services

7. Filgrastim Biosimilars Market Regional And Country Analysis

7.1. Global Filgrastim Biosimilars Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
7.2. Global Filgrastim Biosimilars Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Filgrastim Biosimilars Market

8.1. Asia-Pacific Filgrastim Biosimilars Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
8.2. Asia-Pacific Filgrastim Biosimilars Market, Segmentation By Type Of Manufacturing, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.3. Asia-Pacific Filgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.4. Asia-Pacific Filgrastim Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Filgrastim Biosimilars Market

9.1. China Filgrastim Biosimilars Market Overview
9.2. China Filgrastim Biosimilars Market, Segmentation By Type Of Manufacturing, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.3. China Filgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.4. China Filgrastim Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Filgrastim Biosimilars Market

10.1. India Filgrastim Biosimilars Market, Segmentation By Type Of Manufacturing, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.2. India Filgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.3. India Filgrastim Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Filgrastim Biosimilars Market

11.1. Japan Filgrastim Biosimilars Market Overview
11.2. Japan Filgrastim Biosimilars Market, Segmentation By Type Of Manufacturing, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.3. Japan Filgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.4. Japan Filgrastim Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Filgrastim Biosimilars Market

12.1. Australia Filgrastim Biosimilars Market, Segmentation By Type Of Manufacturing, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.2. Australia Filgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.3. Australia Filgrastim Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Filgrastim Biosimilars Market

13.1. Indonesia Filgrastim Biosimilars Market, Segmentation By Type Of Manufacturing, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.2. Indonesia Filgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.3. Indonesia Filgrastim Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Filgrastim Biosimilars Market

14.1. South Korea Filgrastim Biosimilars Market Overview
14.2. South Korea Filgrastim Biosimilars Market, Segmentation By Type Of Manufacturing, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.3. South Korea Filgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.4. South Korea Filgrastim Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Filgrastim Biosimilars Market

15.1. Western Europe Filgrastim Biosimilars Market Overview
15.2. Western Europe Filgrastim Biosimilars Market, Segmentation By Type Of Manufacturing, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.3. Western Europe Filgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.4. Western Europe Filgrastim Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Filgrastim Biosimilars Market

16.1. UK Filgrastim Biosimilars Market, Segmentation By Type Of Manufacturing, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.2. UK Filgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.3. UK Filgrastim Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Filgrastim Biosimilars Market

17.1. Germany Filgrastim Biosimilars Market, Segmentation By Type Of Manufacturing, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.2. Germany Filgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.3. Germany Filgrastim Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Filgrastim Biosimilars Market

18.1. France Filgrastim Biosimilars Market, Segmentation By Type Of Manufacturing, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.2. France Filgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.3. France Filgrastim Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Filgrastim Biosimilars Market

19.1. Italy Filgrastim Biosimilars Market, Segmentation By Type Of Manufacturing, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.2. Italy Filgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.3. Italy Filgrastim Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Filgrastim Biosimilars Market

20.1. Spain Filgrastim Biosimilars Market, Segmentation By Type Of Manufacturing, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.2. Spain Filgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.3. Spain Filgrastim Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Filgrastim Biosimilars Market

21.1. Eastern Europe Filgrastim Biosimilars Market Overview
21.2. Eastern Europe Filgrastim Biosimilars Market, Segmentation By Type Of Manufacturing, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.3. Eastern Europe Filgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.4. Eastern Europe Filgrastim Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Filgrastim Biosimilars Market

22.1. Russia Filgrastim Biosimilars Market, Segmentation By Type Of Manufacturing, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.2. Russia Filgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.3. Russia Filgrastim Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Filgrastim Biosimilars Market

23.1. North America Filgrastim Biosimilars Market Overview
23.2. North America Filgrastim Biosimilars Market, Segmentation By Type Of Manufacturing, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.3. North America Filgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.4. North America Filgrastim Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Filgrastim Biosimilars Market

24.1. USA Filgrastim Biosimilars Market Overview
24.2. USA Filgrastim Biosimilars Market, Segmentation By Type Of Manufacturing, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.3. USA Filgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.4. USA Filgrastim Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Filgrastim Biosimilars Market

25.1. Canada Filgrastim Biosimilars Market Overview
25.2. Canada Filgrastim Biosimilars Market, Segmentation By Type Of Manufacturing, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.3. Canada Filgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.4. Canada Filgrastim Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Filgrastim Biosimilars Market

26.1. South America Filgrastim Biosimilars Market Overview
26.2. South America Filgrastim Biosimilars Market, Segmentation By Type Of Manufacturing, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.3. South America Filgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.4. South America Filgrastim Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Filgrastim Biosimilars Market

27.1. Brazil Filgrastim Biosimilars Market, Segmentation By Type Of Manufacturing, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.2. Brazil Filgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.3. Brazil Filgrastim Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Filgrastim Biosimilars Market

28.1. Middle East Filgrastim Biosimilars Market Overview
28.2. Middle East Filgrastim Biosimilars Market, Segmentation By Type Of Manufacturing, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.3. Middle East Filgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.4. Middle East Filgrastim Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Filgrastim Biosimilars Market

29.1. Africa Filgrastim Biosimilars Market Overview
29.2. Africa Filgrastim Biosimilars Market, Segmentation By Type Of Manufacturing, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.3. Africa Filgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.4. Africa Filgrastim Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Filgrastim Biosimilars Market Competitive Landscape And Company Profiles

30.1. Filgrastim Biosimilars Market Competitive Landscape
30.2. Filgrastim Biosimilars Market Company Profiles
- 30.2.1. Teva Pharmaceutical Industries Ltd Overview, Products and Services, Strategy and Financial Analysis
- 30.2.2. Novartis International AG Overview, Products and Services, Strategy and Financial Analysis
- 30.2.3. Biocon Limited Overview, Products and Services, Strategy and Financial Analysis
- 30.2.4. Intas Biopharmaceuticals Overview, Products and Services, Strategy and Financial Analysis
- 30.2.5. Dr. Reddy's Laboratories Overview, Products and Services, Strategy and Financial Analysis

31. Filgrastim Biosimilars Market Other Major And Innovative Companies

31.1. Pfizer
31.2. Cadila Healthcare Ltd
31.3. Reliance Life Science Pvt. Ltd
31.4. Gennova Biopharmaceuticals (Emcure)
31.5. Sandoz Pty Ltd
31.6. Mylan
31.7. Lupin Limited
31.8. Coherus Biosciences Inc.
31.9. North China Pharmaceutical Corporation
31.10. Tonghua Dongbaoare
31.11. Beijing SL Pharmaceutical
31.12. Fuji Pharma
31.13. Adello Biologics
31.14. Apobiologix (Apotex)
31.15. Hospira

32. Global Filgrastim Biosimilars Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Filgrastim Biosimilars Market

34. Recent Developments In The Filgrastim Biosimilars Market

35. Filgrastim Biosimilars Market High Potential Countries, Segments and Strategies

35.1 Filgrastim Biosimilars Market In 2029 - Countries Offering Most New Opportunities
35.2 Filgrastim Biosimilars Market In 2029 - Segments Offering Most New Opportunities
35.3 Filgrastim Biosimilars Market In 2029 - Growth Strategies
- 35.3.1 Market Trend Based Strategies
- 35.3.2 Competitor Strategies

36. Appendix

36.1. Abbreviations
36.2. Currencies
36.3. Historic And Forecast Inflation Rates
36.4. Research Inquiries
36.5. The Business Research Company
36.6. Copyright And Disclaimer